Healthcare provider profile · identity verified

Genet Lao Loo, ARNP

Nurse Practitioner · MIAMI, FL · NPI 1164124780

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	303	143
Gabapentin	Gabapentin	278	111
Atorvastatin Calcium	Atorvastatin Calcium	272	151
Amlodipine Besylate	Amlodipine Besylate	250	124
Losartan Potassium	Losartan Potassium	245	125
Lisinopril	Lisinopril	207	99
Glipizide	Glipizide	198	73
Metformin Hcl	Metformin Hcl	161	79
Furosemide	Furosemide	155	80
Nifedipine Er	Nifedipine	148	79
Diclofenac Sodium	Diclofenac Sodium	137	94
Fluticasone Propionate	Fluticasone Propionate	114	79
Baclofen	Baclofen	108	70
Metoprolol Succinate	Metoprolol Succinate	95	44
Albuterol Sulfate Hfa	Albuterol Sulfate	94	42
Hydrochlorothiazide	Hydrochlorothiazide	93	53
Pantoprazole Sodium	Pantoprazole Sodium	91	64
Tamsulosin Hcl	Tamsulosin Hcl	84	43
Trazodone Hcl	Trazodone Hcl	84	27
Alendronate Sodium	Alendronate Sodium	82	33
Carvedilol	Carvedilol	81	38
Famotidine	Famotidine	75	45
Levothyroxine Sodium	Levothyroxine Sodium	72	29
Metformin Hcl Er	Metformin Hcl	72	28
Metoprolol Tartrate	Metoprolol Tartrate	64	34
Meloxicam	Meloxicam	61	47
Vitamin D2	Ergocalciferol (Vitamin D2)	59	35
Triamcinolone Acetonide	Triamcinolone Acetonide	51	34
Memantine Hcl	Memantine Hcl	48	19
Hydralazine Hcl	Hydralazine Hcl	47	20
Omeprazole	Omeprazole	45	29
Tizanidine Hcl	Tizanidine Hcl	44	31
Donepezil Hcl	Donepezil Hcl	42	21
Meclizine Hcl	Meclizine Hcl	42	30
Simvastatin	Simvastatin	42	21
Jardiance	Empagliflozin	41	17
Mirtazapine	Mirtazapine	41	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	40	17
Ibuprofen	Ibuprofen	39	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	22
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	37	15
Azithromycin	Azithromycin	36	36
Farxiga	Dapagliflozin Propanediol	36	14
Lactulose	Lactulose	36	20
Clopidogrel	Clopidogrel Bisulfate	33	17
Warfarin Sodium	Warfarin Sodium	33	suppressed
Eliquis	Apixaban	32	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	31	14
Allopurinol	Allopurinol	30	16
Clonidine Hcl	Clonidine Hcl	28	15
Potassium Chloride	Potassium Chloride	25	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	24	24
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Finasteride	Finasteride	21	suppressed
Spironolactone	Spironolactone	21	12
Sildenafil Citrate	Sildenafil Citrate	20	suppressed
Methylprednisolone	Methylprednisolone	19	18
Atenolol	Atenolol	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	11
Latanoprost	Latanoprost	17	suppressed
Megestrol Acetate	Megestrol Acetate	17	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	17	suppressed
Ciclopirox	Ciclopirox	16	12
Janumet	Sitagliptin Phos/Metformin Hcl	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Ammonium Lactate	Ammonium Lactate	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	14
Labetalol Hcl	Labetalol Hcl	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Primidone	Primidone	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Montelukast Sodium	Montelukast Sodium	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Prednisone	Prednisone	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Ramipril	Ramipril	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error